CircNOX4 promotes proliferation and resistance by regulating the hsa-miR-6884-5p/YWHAG Axis and ERK signaling pathway in cholangiocarcinoma
- PMID: 40736609
- DOI: 10.1007/s10142-025-01668-0
CircNOX4 promotes proliferation and resistance by regulating the hsa-miR-6884-5p/YWHAG Axis and ERK signaling pathway in cholangiocarcinoma
Abstract
The biological function of circular RNAs (circRNAs) has been increasingly implicated in tumor drug resistance. However, their role in intrahepatic cholangiocarcinoma (ICC) remains poorly understood, and the underlying mechanisms are largely unexplored. In this study, we identified a key circRNA, circNOX4, through data mining and experimental validation in ICC. We found that circNOX4 was significantly upregulated in ICC tissues and its expression correlated with advanced clinicopathological features. Functional assays demonstrated that circNOX4 promoted ICC cell proliferation and tumor growth both in vitro and in vivo. Mechanistically, circNOX4 acted as a molecular sponge for hsa-miR-6884-5p, thereby upregulating YWHAG expression. YWHAG, in turn, interacted with RAF1, enhancing its phosphorylation and activating the ERK signaling pathway. This led to the nuclear translocation of phosphorylated ERK and subsequent promotion of ICC progression. Furthermore, we found that circNOX4 attenuated the anti-tumor efficacy of Trametinib. In summary, circNOX4 contributes to ICC progression and drug resistance through the hsa-miR-6884-5p/YWHAG/ERK axis, and may serve as a potential diagnostic marker, prognostic indicator, and therapeutic target in ICC.
Keywords: Cholangiocarcinoma; CircNOX4; RAF/MEK/ERK signaling; Resistance; YWHAG.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Conflict of interest: The authors have declared no conflicts of interest. Informed consent: allowing the use of retrospective data at the time of admission was obtained from all patients included in the study, and specific consent was waived. Clinical trial number: Not applicable.
Similar articles
-
Circ_0084927 promotes progression of intrahepatic cholangiocarcinoma by sponging miR-4725-5p to activate the PDPK1/AKT/mTOR signaling pathway.Cell Signal. 2025 Oct;134:111965. doi: 10.1016/j.cellsig.2025.111965. Epub 2025 Jun 26. Cell Signal. 2025. PMID: 40581264
-
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma.Cancer Commun (Lond). 2025 Aug;45(8):1038-1071. doi: 10.1002/cac2.70036. Epub 2025 May 29. Cancer Commun (Lond). 2025. PMID: 40443016 Free PMC article.
-
PTP4A1 promotes intrahepatic cholangiocarcinoma development and progression by interacting with PTEN and activating the PI3K/AKT/GSKα axis.Oncol Rep. 2025 Oct;54(4):125. doi: 10.3892/or.2025.8958. Epub 2025 Aug 1. Oncol Rep. 2025. PMID: 40747713 Free PMC article.
-
Systemic treatments for metastatic cutaneous melanoma.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
-
The diverse roles of circular RNAs in cholangiocarcinoma.Med Oncol. 2025 Aug 29;42(10):455. doi: 10.1007/s12032-025-03018-3. Med Oncol. 2025. PMID: 40879959 Review.
References
-
- Bahar ME, Kim HJ, Kim DR (2023) Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther 8:455
-
- Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J-W, Patel T, Pawlik TM, Gores GJ (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289
-
- Chen XQ, Chen JG, Zhang Y, Hsiao WWL, Yu ACH (2003) 14-3-3gamma is upregulated by in vitro ischemia and binds to protein kinase Raf in primary cultures of astrocytes. Glia 42:315–324
-
- Chen K, Zhang J, Beeraka NM, Li J, Sinelnikov MY, Zhang X, Cao Y, Zakharova DK, Nikolenko VN, Reshetov IV et al (2023) Novel perspectives on Nanotechnological and biomedical implications of monotherapy or combination regimen of lactoferrin. Curr Pharm Des 29:1579–1591
-
- Hammond SM (2015) An overview of MicroRNAs. Adv Drug Deliv Rev 87
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous